Travatan and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Travatan (travoprost), especially for people who are female, 60+ old, also take Otezla, and have High blood pressure.

The phase IV clinical study analyzes which people have Psoriasis when taking Travatan. It is created by eHealthMe based on reports of 12,807 people who have side effects when taking Travatan from the FDA, and is updated regularly.

What is Travatan?

Travatan has active ingredients of travoprost. It is often used in glaucoma. eHealthMe is studying from 13,103 Travatan users. Check the latest studies of Travatan.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,474 drugs and 1,695 conditions by eHealthMe. Check the latest studies of Psoriasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

12,807 people reported to have side effects when taking Travatan.
Among them, 35 people (0.27%) have Psoriasis.

Among these 35 people:

What is the gender of people who have Psoriasis when taking Travatan? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Psoriasis when taking Travatan? *

What are other drugs people take besides Travatan? *

What are other side effects people have besides Psoriasis? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 14.29%
Hypoaesthesia (reduced sense of touch or sensation): 4 people, 11.43%
Fall: 4 people, 11.43%
Drug Ineffective: 4 people, 11.43%
Staphylococcal Infection (an infection with staphylococcus bacteria): 4 people, 11.43%
Joint Pain: 3 people, 8.57%
Skin Haemorrhage (bleeding into skin): 3 people, 8.57%
Gait Disturbance: 3 people, 8.57%
Infection: 3 people, 8.57%
Itching: 3 people, 8.57%

What are the existing conditions these people have? *

Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 5 people, 14.29%
High Blood Pressure: 5 people, 14.29%
Blood Pressure Abnormal: 2 people, 5.71%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 5.71%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 5.71%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 5.71%
Diabetes: 2 people, 5.71%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.71%
Borderline Glaucoma: 1 person, 2.86%
Breast Cancer Female: 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Travatan and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Travatan:

Travatan (13,103 reports)

Psoriasis treatments and more:

Psoriasis (508,164 reports)

Browse all side effects of Travatan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,474 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,695 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on travoprost (the active ingredients of Travatan) and Travatan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.